Loading organizations...
Crystal Horizon Investments operates as an investment entity focused on deploying capital into promising growth-stage companies, particularly within technologically advanced sectors. The firm engages in strategic financing, as demonstrated by its participation in a Series D funding round for a therapeutics innovator, signaling a preference for enterprises positioned for significant expansion that require substantial capital infusions.
Established to identify and capitalize on emergent market opportunities, Crystal Horizon Investments commenced its known activities by providing venture capital to developing ventures. While specific founding details are not extensively publicized, the firm's strategic involvement in crucial funding rounds indicates a foundational objective to support and nurture innovative business development.
The firm primarily functions as a financial partner for pioneering startups, aiding their trajectory towards expansion and market commercialization. Crystal Horizon Investments aims to foster the advancement of transformative technologies by supplying essential early to mid-stage financing, ultimately seeking to generate substantial value through robust portfolio company growth and successful market exits.
Crystal Horizon Investments has 1 tracked investment across 1 company. The latest tracked deal is $39.0M Series D in Rani Therapeutics in September 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2017 | Rani Therapeutics | $39.0M Series D | — | Byers Capital, Founders' Co OP, Seven Seven SIX, Susa Ventures, Y Combinator, Justin Mateen, AstraZeneca, Bossanova Investimentos, Buttonwood, Cathay Innovation, GV, Novartis, Pacific Venture Opportunity Fund, Pinemount Investments |